Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Til Menge

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Neurology|June 23, 2012
Neuromyelitis optica following human papillomavirus vaccinationTil Menge, Bruce Cree, Andreas Saleh, et al.
Neuropsychiatric Disease and Treatment|May 1, 2025
Beyond Anxiety and Depression: Multidimensional Psychiatric Screening for Neurological Patients Based on HADS and BSI-53Milenko Kujovic, Daniel Benz, Bruno Baumann, et al.
Neurochemistry International|August 14, 2010
Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes virusesJohann Sellner, Sabine Cepok, Sudhakar Reddy Kalluri, et al.
Drugs|November 20, 2008
Disease-modifying agents for multiple sclerosis: recent advances and future prospectsTil Menge, Martin S Weber, Bernhard Hemmer, et al.
Annals of Clinical and Translational Neurology|February 3, 2015
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20bJens Ingwersen, Til Menge, Britta Wingerath, et al.
Frontiers in Neurology|July 22, 2017
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon BetaKathleen Ingenhoven, Daniel Kramer, Poul Erik Jensen, et al.
Archives of Neurology|August 11, 2010
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Clemens Warnke, Til Menge, Hans-Peter Hartung, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 25, 2021
Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune EncephalitisPhilipp Schwenkenbecher, Thomas Skripuletz, Peter Lange, et al.
Drugs|December 18, 2007
Pharmacological treatment of early multiple sclerosisOlaf Stüve, Jeffrey L Bennett, Bernhard Hemmer, et al.
Frontiers in Neurology|March 27, 2025
Stroke aftercare in Germany: findings from an online survey in the outpatient setting of a neurovascular networkJohn-Ih Lee, Robin Jansen, Jan F Cornelius, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Neurology|June 23, 2012
Neuromyelitis optica following human papillomavirus vaccinationTil Menge, Bruce Cree, Andreas Saleh, et al.
Neuropsychiatric Disease and Treatment|May 1, 2025
Beyond Anxiety and Depression: Multidimensional Psychiatric Screening for Neurological Patients Based on HADS and BSI-53Milenko Kujovic, Daniel Benz, Bruno Baumann, et al.
Neurochemistry International|August 14, 2010
Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes virusesJohann Sellner, Sabine Cepok, Sudhakar Reddy Kalluri, et al.
Drugs|November 20, 2008
Disease-modifying agents for multiple sclerosis: recent advances and future prospectsTil Menge, Martin S Weber, Bernhard Hemmer, et al.
Annals of Clinical and Translational Neurology|February 3, 2015
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20bJens Ingwersen, Til Menge, Britta Wingerath, et al.
Frontiers in Neurology|July 22, 2017
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon BetaKathleen Ingenhoven, Daniel Kramer, Poul Erik Jensen, et al.
Archives of Neurology|August 11, 2010
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Clemens Warnke, Til Menge, Hans-Peter Hartung, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 25, 2021
Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune EncephalitisPhilipp Schwenkenbecher, Thomas Skripuletz, Peter Lange, et al.
Drugs|December 18, 2007
Pharmacological treatment of early multiple sclerosisOlaf Stüve, Jeffrey L Bennett, Bernhard Hemmer, et al.
Frontiers in Neurology|March 27, 2025
Stroke aftercare in Germany: findings from an online survey in the outpatient setting of a neurovascular networkJohn-Ih Lee, Robin Jansen, Jan F Cornelius, et al.
Pageof 5